Mylan Says Novartis' Lotrel Patent Invalid
Mylan Pharmaceuticals Inc. has struck back at Novartis International AG, claiming that the patent Novartis asserted when it sued Mylan over the hypertension drug Lotrel is invalid....To view the full article, register now.
Already a subscriber? Click here to view full article